Presenters |
Daniela Cilloni, MD, PhD
University of Turin
Turin, Italy
Meletios Dimopoulos, MD
University of Athens
Athens, Greece
Claire Harrison, DM, FRCP, FRCPath
Guy's and St Thomas' National Health
Service Foundation Trust
London, United Kingdom
Andreas Hochhaus, MD
Heidelberg University
Mannheim, Germany
Timothy P. Hughes, MD, MBBS
Royal Adelaide Hospital
Adelaide, Australia
Elias Jabbour, MD
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, United States
Hyacinthe Johnson-Ansah, MD
University Hospital Caen
Caen, France
Jean-Jacques Kiladjian, MD, PhD
Saint-Louis Hospital
Paris, France
|
Rami Komrokji, MD
H. Lee Moffitt Cancer Center
Tampa, Florida, United States
John Mascarenhas, MD
The Mount Sinai Hospital
New York, United States
Ruben Mesa, MD
Mayo Clinic
Scottsdale, Arizona, United States
Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Giuseppe Saglio, MD
University of Turin
Turin, Italy
Srdan Verstovsek, MD, PhD
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, United States
Ravi Vij, MD
Washington University
Saint Louis, Missouri, United States
|
|
 TARGET AUDIENCE | This educational activity is intended for oncologists, hematologists, and other healthcare professionals based outside of the United States who are interested in the management of patients with hematologic malignancies. |
LEARNING OBJECTIVES | After successful completion of this educational activity, participants should be able to:
- Examine the efficacy and safety of front-line treatment options for chronic myeloid leukemia
- Discuss strategies for optimizing current standards of care for patients with Philadelphia chromosome–negative myeloproliferative neoplasms
- Analyze the impact of iron chelation therapy on survival in patients with myelodysplastic syndromes
- Evaluate recent clinical trial data regarding therapeutic advances in the management of patients with multiple myeloma, and evaluate the practical implications of these data
|
Disclosure of Conflicts of Interest | prIME Oncology assesses conflicts of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of activities. All relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity. |
Disclosure of Unlabeled Use | This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings. |
Disclaimer | Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. |
|
|
|
Organizer | This is a prIME oncology activity.
|
SUPPORT | Support for this educational activity is provided by Novartis Oncology.
|
|
